Nature Communications (Feb 2023)

Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase

  • Sebenzile K. Myeni,
  • Peter J. Bredenbeek,
  • Robert C. M. Knaap,
  • Tim J. Dalebout,
  • Shessy Torres Morales,
  • Igor A. Sidorov,
  • Marissa E. Linger,
  • Nadia Oreshkova,
  • Sophie van Zanen-Gerhardt,
  • Serge A. L. Zander,
  • Luis Enjuanes,
  • Isabel Sola,
  • Eric J. Snijder,
  • Marjolein Kikkert

DOI
https://doi.org/10.1038/s41467-023-36754-z
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 15

Abstract

Read online

In this work, authors provide a proof-of-concept study showing that deubiquitinating enzyme inactivation in MERS-CoV leads to attenuation in mice, and protection against a lethal challenge.